Core Insights - Prenetics is positioning itself as a unique player in the supplement industry by integrating a Bitcoin treasury strategy alongside its core business operations [2][4]. - The company aims to achieve over $100 million in annual recurring revenue within a year of launching its IM8 brand, highlighting its rapid growth and innovative business model [3]. Financial Overview - Prenetics currently holds 248.42 BTC, with a net asset value (NAV) of approximately $28 million and an average purchase price of about $108,600 per BTC [5][1]. - The company has $63.5 million in cash, which includes various current assets such as cash equivalents and trade receivables [1][7]. Strategic Initiatives - Prenetics initiated its Bitcoin treasury strategy in June 2025, committing a significant portion of its balance sheet to Bitcoin and planning to acquire one Bitcoin daily [4][6]. - The company has already purchased 187.42 BTC for around $20 million at an average price of $106,712 per BTC, demonstrating its commitment to this strategy [5]. Market Position - The IM8 brand is recognized as one of the fastest-growing supplement brands, reflecting Prenetics' innovative approach at the intersection of health and wealth [2][3]. - Prenetics is set to present at Token 2049, a major crypto and blockchain conference, further establishing its presence in the digital asset space [1][9].

Core Insights - Presearch.com, a decentralized Web3 search engine, has announced that its token PRE is now trading on Coinbase and Gemini, enhancing its accessibility and user engagement [1][2][3] Group 1: Token Availability and Trading - PRE is available for trading on Coinbase through the Coinbase DEX, which is currently accessible to approximately one million users in the U.S., excluding New York State [2] - On Gemini, PRE is available across nearly 60 countries and all 50 U.S. states, broadening its market reach [2] Group 2: Ecosystem and Business Model - The integration of PRE on major platforms like Coinbase and Gemini is expected to streamline token acquisition for U.S. advertisers, facilitating easier payment for services such as Presearch takeover ads and the AI chatbot PrePGPT [3] - The PRE token is central to the Presearch ecosystem, built on both Coinbase's Base Layer 2 blockchain and the Ethereum network, aligning incentives among users, advertisers, and operators [3] Group 3: Decentralization and Infrastructure - Presearch operates on a hybrid Proof-of-Work model with over 30,000 community-operated nodes, ensuring true decentralization in both infrastructure and incentives [4] - The nodes are rewarded based on search volume, PRE tokens staked, reliability scores, and geographic distribution, promoting a robust decentralized network [4] Group 4: User Empowerment and Privacy - Presearch aims to provide a privacy-first search experience, allowing users to own their data and rewards, thus redefining the role of search in the Web3 ecosystem [5][7] - The platform addresses issues like declining click-through rates and invasive data practices, offering a solution that emphasizes privacy, ownership, and economic empowerment [5]

Core Viewpoint - Contango ORE, Inc. has successfully completed a public offering of common shares, raising approximately $50 million to fund its mining projects and general corporate purposes [1][2]. Group 1: Offering Details - The offering consisted of 1,975,000 common shares priced at $20.00 each and included a pre-funded warrant for 525,000 shares at $19.99 each, resulting in gross proceeds of around $50 million before expenses [1]. - Canaccord Genuity acted as the Sole Bookrunner, with Cormark Securities as Lead Manager and other firms as Co-Managers for the offering [3]. Group 2: Use of Proceeds - The net proceeds will be allocated to advance the Lucky Shot project towards a mine production decision within two years, involving drilling and underground development [2]. - Funds will also support the Johnson Tract project, including road construction, camp winterization, exploration tunnel construction, and feasibility planning, pending necessary permits [2]. Group 3: Company Overview - Contango is engaged in gold exploration in Alaska, holding a 30% interest in the Peak Gold project and leases on the Johnson Tract and Lucky Shot projects, along with ownership of additional mining claims [5].

Core Viewpoint - Prenetics Global Limited (PRE) is identified as a strong momentum stock with a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating potential for significant near-term gains [3][4][12]. Company Performance - Over the past week, PRE shares have increased by 19.11%, while the Zacks Medical - Biomedical and Genetics industry remained flat during the same period [6]. - In a longer timeframe, PRE's monthly price change is 85.14%, significantly outperforming the industry's 0.92% [6]. - Over the past quarter, PRE shares have risen by 73.2%, and over the last year, they have surged by 249.49%, compared to the S&P 500's increases of 9.31% and 17.01%, respectively [7]. Trading Volume - The average 20-day trading volume for PRE is 118,382 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the last two months, one earnings estimate for PRE has been revised upward, while none have been revised downward, leading to an increase in the consensus estimate from -$2.71 to -$2.56 [10]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions noted [10].

Core Viewpoint - Contango ORE, Inc. has successfully priced its underwritten public offering of common shares, raising approximately $50 million to fund its mining projects and general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of 1,975,000 shares priced at $20.00 per share and includes a pre-funded warrant for 525,000 shares at $19.99 each, with gross proceeds expected to be around $50 million before expenses [1]. - The closing of the offering is anticipated to occur on or about September 26, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - Net proceeds will be allocated to advance the Lucky Shot project towards a mine production decision over the next two years, including drilling and underground development [2]. - Funds will also support the Johnson Tract project, focusing on road construction, camp winterization, exploration tunnel construction, and feasibility-level mine planning [2]. - Remaining proceeds will be utilized for general corporate purposes, including working capital [2]. Group 3: Management and Underwriters - Canaccord Genuity is the Sole Bookrunner for the offering, with Cormark Securities as Lead Manager and Maxim Group LLC, Roth Capital Partners, and Freedom Capital Markets as Co-Managers [3]. Group 4: Company Overview - Contango ORE, Inc. is engaged in gold exploration in Alaska, holding interests in multiple projects, including a 30% stake in Peak Gold, LLC, and leases on the Johnson Tract and Lucky Shot projects [6]. - The company has approximately 8,600 acres of peripheral mining claims and a 100% interest in about 145,000 acres of State of Alaska mining claims [6].

Company Highlights - Cidara Therapeutics Inc. (CDTX) reached a 52-week high of $87.19 as it advances its development plan for CD388, a non-vaccine preventive treatment for seasonal influenza, with enrollment in a Phase 3 study expected to start by September 2025 targeting 6,000 participants [1] - Maze Therapeutics Inc. (MAZE) saw its stock rise to a 52-week high of $27.09 following positive Phase 1 clinical results for MZE782, an oral therapy for Phenylketonuria and chronic kidney disease, with plans to enter Phase 2 studies in 2026 [3][4] - Medpace Holdings Inc. (MEDP) is set to report Q3 2025 financial results on October 22, 2025, and has raised its full-year guidance twice, indicating strong operational momentum, with the stock hitting a 52-week high of $506.55 [5][6] - Monopar Therapeutics Inc. (MNPR) rebounded from potential Nasdaq delisting to a 52-week high of $73.75, planning to seek approval for ALXN1840 for Wilson disease in early 2026, supported by long-term clinical data [7][8] - Prenetics Global Limited (PRE) projects 2025 revenue between $85 million and $100 million, a significant increase from $30.6 million in 2024, with its new wellness brand IM8 Health on track for $100 million in annual recurring revenue [9][10] - Protagonist Therapeutics Inc. (PTGX) is nearing a major milestone with Icotrokinra for psoriasis, having submitted a regulatory application to the FDA and EMA in July 2025, with the stock reaching a 52-week high of $66.70 [11][12] - uniQure N.V. (QURE) announced positive results from its Phase I/II study of AMT-130 for Huntington's disease, planning to submit a Biologics License Application in Q1 2026, with the stock soaring over 200% to a 52-week high of $51.21 [13][14] - Rezolute Inc. (RZLT) surged to a 52-week high of $9.02 ahead of topline results from its pivotal Phase III trial for hypoglycemia treatment, expected in December [15][16] - United Therapeutics Corp. (UTHR) reached a 52-week high of $442.01 as anticipation builds for data from the TETON-2 study of nebulized Tyvaso in idiopathic pulmonary fibrosis, with positive results reported earlier [17][18]

Company Strategy - Nasdaq-listed healthcare firm Prenetics holds 228 Bitcoin [1] - Prenetics is buying 1 Bitcoin per day for its treasury [1] Market Trend - The trend of companies holding Bitcoin for their treasury may become more common [1]

Cryptocurrency Holdings - Prenetics, a NASDAQ-listed company, currently holds 228 BTC [1] - The company is purchasing 1 BTC per day [1]

Revenue Growth - Revenue for the first half of 2025 grew 452.1% to $32.3 million year-over-year[1] - IM8 achieved $5.9 million in revenue for August 2025, with a compound annual growth rate (CAGR) of over 3,100%[1][8] - Prenetics increased its full-year 2025 revenue guidance range to $85 - $100 million[1][12] - Revenue for the six months ended June 30, 2025, was $32,276,000, a significant increase from $5,846,000 in the same period of 2024, representing a growth of 450%[24] - Revenue for the three months ended June 30, 2025, was $17,680,000, up from $2,544,000 in the same period of 2024, a growth of 594%[25] - Total revenue from continuing operations for the six months ended June 30, 2025, was $32,276, significantly up from $5,846 in the same period of 2024, reflecting a growth of 451.5%[27] - CircleDNA revenue for the six months ended June 30, 2025, was $4,752, down from $5,846 in 2024, a decrease of 18.7%[27] - IM8 generated revenue of $15,486 for the six months ended June 30, 2025, with no revenue reported in the same period of 2024[27] Financial Performance - Adjusted EBITDA loss for the second quarter of 2025 was $(4.1) million, a decrease of 8.7% compared to the first quarter of 2025[5] - Loss from operations for the six months ended June 30, 2025, was $18,427,000, compared to a loss of $14,472,000 in the same period of 2024, reflecting a deterioration of 27%[24] - Loss for the period for the six months ended June 30, 2025, was $23,743,000, compared to a loss of $20,197,000 in the same period of 2024, an increase of 13%[24] - Basic loss per share for the six months ended June 30, 2025, was $(1.74), compared to $(1.58) in the same period of 2024[24] - Loss from continuing operations for the three months ended June 30, 2025, was $10,921,000, compared to $8,898,000 in the same period of 2024, an increase of 23%[25] - For the six months ended June 30, 2025, the loss for the period under IFRS was $23,743, compared to a loss of $20,197 for the same period in 2024, representing an increase of 12.5%[26] - Adjusted EBITDA (Non-IFRS) for the six months ended June 30, 2025, was $(8,657), worsening from $(5,955) in the same period of 2024, indicating a decline of 45.4%[26] - For the three months ended June 30, 2025, the loss for the period under IFRS was $12,727, compared to $11,146 in the same period of 2024, an increase of 14.2%[26] Assets and Cash Position - Total assets as of June 30, 2025, were $199,106,000, down from $206,197,000 as of March 31, 2025, a decrease of 3%[23] - Cash and cash equivalents decreased to $17,249,000 as of June 30, 2025, from $43,153,000 as of March 31, 2025, a decline of 60%[23] - Total equity attributable to equity shareholders decreased to $150,982,000 as of June 30, 2025, from $161,188,000 as of March 31, 2025, a decline of 6%[23] - Current assets under IFRS as of June 30, 2025, were $44,037, a decrease from $75,747 as of December 31, 2024, representing a decline of 42.0%[27] - Adjusted current assets (Non-IFRS) as of June 30, 2025, were $90,342, an increase from $75,747 as of December 31, 2024, indicating a growth of 19.3%[27] Strategic Initiatives - IM8's new customer subscription rate exceeded 80% with an average order value of $110[8] - Prenetics plans to achieve breakeven by Q1 2026, supported by a strong balance sheet of $90 million in cash and BTC[3][12] - Prenetics initiated a disciplined Bitcoin treasury strategy, starting with a $20 million purchase of Bitcoin in June 2025[10] - The divestment of ACT Genomics is expected to provide gross proceeds of $46.3 million, with closing anticipated in Q4 2025[13] Bitcoin Holdings - The company held 228.42 Bitcoin valued at $26.1 million as of September 10, 2025, with an unrealized gain of approximately $1.6 million[5][10] Employee Compensation - The total employee equity-settled share-based payment expenses for the six months ended June 30, 2025, were $2,005, down from $3,273 in 2024, a decrease of 38.8%[28] Discontinued Operations - The loss from discontinued operations, net of tax, for the six months ended June 30, 2025, was $3,979, compared to $5,015 in the same period of 2024, a reduction of 20.7%[26]

Financial Performance - Company reported a revenue of $32.3 million for the first half of 2025, reflecting a year-over-year increase of 452.1% compared to the first half of 2024 [1][5] - In the second quarter of 2025, revenue reached $17.7 million, an increase of 594.9% compared to the second quarter of 2024 [5][30] - Gross profit for the first half of 2025 was $13.2 million, up 166.4% from the same period in 2024 [5] - Adjusted EBITDA loss for the first half of 2025 was $(8.7) million, which is an increase of 45.4% compared to the first half of 2024 [5] Business Unit Performance - IM8 generated $15.5 million in revenue for the first half of 2025, with a monthly revenue of $5.9 million in August 2025, indicating a CAGR of over 3,100% [6][12] - Europa and CircleDNA contributed $12.0 million and $4.8 million, respectively, to the first half revenue [13][36] - IM8's revenue in the second quarter was $9.8 million, a 70% increase over the first quarter of 2025 [5] Strategic Initiatives - Company has initiated a disciplined Bitcoin treasury strategy, acquiring a total of 228 Bitcoin as of September 10, 2025, with an unrealized gain of approximately $1.6 million [15][16] - Prenetics aims to achieve break-even by Q1 2026 and has increased its full-year 2025 revenue guidance to a range of $85 - $100 million [17][18] Market Position and Brand Development - IM8 has rapidly emerged as one of the fastest-growing supplement brands globally, with over 8 million servings delivered and more than 300,000 customer orders [10][12] - The brand's marketing efforts, including a partnership with Aryna Sabalenka, have significantly enhanced its visibility, generating 233 million views during the US Open [10][11] Financial Health - As of September 10, 2025, the company held $90 million in cash and Bitcoin, remaining debt-free [2][5] - Adjusted current assets were reported at $90.3 million, including $63.5 million in cash [5][38]